Literature DB >> 33407391

Effect of Shenkang on renal fibrosis and activation of renal interstitial fibroblasts through the JAK2/STAT3 pathway.

Tianyu Qin1, You Wu1, Tonghua Liu2, Lili Wu3.   

Abstract

BACKGROUND: Activation of renal fibroblasts is a critical mechanism in the process of renal fibrosis. As a commonly used herbal formula, Shenkang (SK) has been found to attenuate renal fibrosis and renal parenchyma destruction. However, the effect of SK on renal fibroblast activation in unilateral ureteral obstruction (UUO) mice and its molecular mechanism remain undetermined. The present study was performed to elucidate the effect of SK on renal fibroblast activation and renal fibrosis, as well as the potential underlying mechanism, in both NRK-49F cells and UUO mice.
METHODS: NRK-49F cells were stimulated with 10 ng/ml TGF-β1 for 48 h. After SK treatment, the CCK-8 method was used to evaluate cell viability. Thirty-six C57BL/6 mice were randomly divided into the sham group, UUO group, angiotensin receptor blocker (ARB) group, and SK high-, moderate- and low-dose groups. UUO was induced in mice except those in the sham group. Drugs were administered 1 day later. On the 13th day, the fractional anisotropy (FA) value was determined by MRI to evaluate the degree of renal fibrosis. After 14 days, serum indexes were assessed. Hematoxylin and eosin (HE) and Sirius red staining were used to observe pathological morphology and the degree of fibrosis of the affected kidney. Western blotting and PCR were used to assess the expression of related molecules in both cells and animals at the protein and gene levels.
RESULTS: Our results showed that SK reduced extracellular matrix (ECM) and α-smooth muscle actin (α-SMA) expression both in vitro and in vivo and attenuated renal fibrosis and the pathological lesion degree after UUO, suppressing JAK2/STAT3 activation. Furthermore, we found that SK regulated the JAK2/STAT3 pathway regulators peroxiredoxin 5 (Prdx5) in vitro and suppressor of cytokine signaling protein 1 (SOCS1) and SOCS3 in vivo.
CONCLUSIONS: These results indicated that SK inhibited fibroblast activation by regulating the JAK2/STAT3 pathway, which may be a mechanism underlying its protective action in renal fibrosis.

Entities:  

Keywords:  Chronic kidney disease; JAK2/STAT3 pathway; Renal fibroblast activation; Renal fibrosis; Shenkang; UUO

Year:  2021        PMID: 33407391     DOI: 10.1186/s12906-020-03180-3

Source DB:  PubMed          Journal:  BMC Complement Med Ther        ISSN: 2662-7671


  32 in total

Review 1.  STAT proteins and transcriptional responses to extracellular signals.

Authors:  C M Horvath
Journal:  Trends Biochem Sci       Date:  2000-10       Impact factor: 13.807

Review 2.  Mechanisms of disease: Fibroblasts--a new look at an old problem.

Authors:  Eric G Neilson
Journal:  Nat Clin Pract Nephrol       Date:  2006-02

3.  Morphometric and visual evaluation of fibrosis in renal biopsies.

Authors:  Alton B Farris; Catherine D Adams; Nicole Brousaides; Patricia A Della Pelle; A Bernard Collins; Ellie Moradi; R Neal Smith; Paul C Grimm; Robert B Colvin
Journal:  J Am Soc Nephrol       Date:  2010-11-29       Impact factor: 10.121

4.  Periplaneta Americana Extract May Attenuate Renal Fibrosis through Inhibiting Janus Tyrosine Kinase 2/Signal Transducer and Activator of Transcription 3 Pathway.

Authors:  Jingsong Liu; Lin Zhou; Liyu He; Ying Zhong; Xiaobai Zhang; Bofei Xiao; Guoyong Liu
Journal:  Pharmacology       Date:  2018-04-17       Impact factor: 2.547

Review 5.  The nature, consequences, and management of neurological disorders in chronic kidney disease.

Authors:  Bahman Jabbari; Nosratola D Vaziri
Journal:  Hemodial Int       Date:  2017-08-11       Impact factor: 1.812

6.  The contribution of chronic kidney disease to the global burden of major noncommunicable diseases.

Authors:  William G Couser; Giuseppe Remuzzi; Shanthi Mendis; Marcello Tonelli
Journal:  Kidney Int       Date:  2011-10-12       Impact factor: 10.612

Review 7.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.

Authors:  J E Darnell; I M Kerr; G R Stark
Journal:  Science       Date:  1994-06-03       Impact factor: 47.728

Review 8.  Cellular and molecular mechanisms of fibrosis.

Authors:  T A Wynn
Journal:  J Pathol       Date:  2008-01       Impact factor: 7.996

Review 9.  The role of the Janus kinase family/signal transducer and activator of transcription signaling pathway in fibrotic renal disease.

Authors:  Futoshi Matsui; Kirstan K Meldrum
Journal:  J Surg Res       Date:  2012-07-17       Impact factor: 2.192

Review 10.  STAT3: an important regulator of multiple cytokine functions.

Authors:  Stanislaw M Stepkowski; Wenhao Chen; Jeremy A Ross; Zsuzsanna S Nagy; Robert A Kirken
Journal:  Transplantation       Date:  2008-05-27       Impact factor: 4.939

View more
  5 in total

Review 1.  Research Progress of Chinese Herbal Medicine Intervention in Renal Interstitial Fibrosis.

Authors:  Xiao-Yuan Liu; Xu-Bin Zhang; Ya-Feng Zhao; Kai Qu; Xiao-Yong Yu
Journal:  Front Pharmacol       Date:  2022-06-13       Impact factor: 5.988

2.  Shenkang Injection for Treating Renal Fibrosis-Metabonomics and Regulation of E3 Ubiquitin Ligase Smurfs on TGF-β/Smads Signal Transduction.

Authors:  Junju Zou; Xiaotao Zhou; Xian Chen; Yuerong Ma; Rong Yu
Journal:  Front Pharmacol       Date:  2022-06-02       Impact factor: 5.988

3.  Shenkang Injection and Its Three Anthraquinones Ameliorates Renal Fibrosis by Simultaneous Targeting IƙB/NF-ƙB and Keap1/Nrf2 Signaling Pathways.

Authors:  Liang-Pu Luo; Ping Suo; Li-Li Ren; Hong-Jiao Liu; Yamei Zhang; Ying-Yong Zhao
Journal:  Front Pharmacol       Date:  2021-12-22       Impact factor: 5.810

Review 4.  Traditional Chinese Medicine in the Treatment of Chronic Kidney Diseases: Theories, Applications, and Mechanisms.

Authors:  Yunlai Wang; Ye Feng; Manman Li; Mo Yang; Gaoxiang Shi; Zihua Xuan; Dengke Yin; Fan Xu
Journal:  Front Pharmacol       Date:  2022-07-18       Impact factor: 5.988

5.  Shenkang injection improves chronic kidney disease by inhibiting multiple renin-angiotensin system genes by blocking the Wnt/β-catenin signalling pathway.

Authors:  Yan-Ni Wang; Hong-Jiao Liu; Li-Li Ren; Ping Suo; Liang Zou; Ya-Mei Zhang; Xiao-Yong Yu; Ying-Yong Zhao
Journal:  Front Pharmacol       Date:  2022-08-17       Impact factor: 5.988

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.